ASTRO: SBRT Ups Survival in Older Early-Stage NSCLC Patients

Share this content:
ASTRO: SBRT Ups Survival in Older Early-Stage NSCLC Patients
ASTRO: SBRT Ups Survival in Older Early-Stage NSCLC Patients

TUESDAY, Sept. 27, 2016 (HealthDay News) -- Stereotactic body radiation therapy (SBRT) seems to provide a significant survival advantage for older patients with early-stage non-small-cell lung cancer (NSCLC), according to two studies presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 25 to 28 in Boston.

In the first study, Andrew Farach, M.D., a radiation oncologist at Houston Methodist Hospital, and colleagues reviewed records for patients 60 and older diagnosed with stage I NSCLC between 2004 and 2012. During that period, two-year survival rates for patients treated with radiation therapy rose from 39 percent in 2004 to 58 percent in 2012. Two-year survival rates for surgery-only patients rose from 79 percent in 2004 to 84 percent in 2014.

The second study focused on 1,671 VA patients with stage I NSCLC. Their average age was 72. Some received standard radiation, and 468 were given SBRT. Researchers found that four-year survival rates for patients who underwent radiation therapy increased from 12.7 percent in 2001 to 28.5 percent in 2011. At the same time, use of SBRT increased from 4.7 percent in 2001 to 60.3 percent in 2011. Further analysis revealed that SBRT was associated with a reduced mortality risk of 28.0 percent compared with conventional radiation therapy.

"It is very rare for a study to show that double the number of patients were likely to be alive at four years due to the introduction of a new treatment," study author Matthew Boyer, M.D., Ph.D., of Duke University in Durham, N.C., said in a news release from the American Society for Radiation Oncology. "We identified that this doubling was due to the introduction of these advanced radiation techniques collectively termed SBRT. Although a number of studies are underway to define the best treatment for stage I NSCLC, our study, and others, indicate that advances in radiation treatment and delivery can improve patient survival and that SBRT should be the standard treatment for patients treated with radiation for stage I NSCLC."

Press Release 1
Press Release 2
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »